Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Mantle-Cell 1Leukemia, Prolymphocytic 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Cytarabine 35Cyclophosphamide 30fludarabine phosphate 24fludarabine 24Rituximab 20Azacitidine 19Methotrexate 17venetoclax 16Peripheral Blood Stem Cell Transplantation 14Dasatinib 12Bendamustine Hydrochloride 12ibrutinib 11Filgrastim 11Busulfan 11Whole-Body Irradiation 10Granulocyte Colony-Stimulating Factor 10Tacrolimus 9Radiotherapy 9Lenalidomide 8Idarubicin 8Decitabine 8Vincristine 7Etoposide 7Dexamethasone 7Daunorubicin 7Cyclosporine 7merphos 6Prednisone 6Melphalan 6Injections 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × sotrastaurin × Other hematologic neoplasm × Clear all
NCT02285244 2017-04-05

Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation

Ohio State University Comprehensive Cancer Center

Phase 2 Withdrawn
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡